The association of adjusted plasma valproic acid concentration with gene polymorphism in patients with epilepsy: a systematic review and meta-analysis.

BACKGROUND

Valproic acid (VPA) is a common antiepileptic drug used to treat both generalized and partial epilepsy. Although there is increasing evidence to suggest that gene polymorphisms are associated with interindividual variability of VPA metabolism, the results are debatable. Therefore, in the present study, we conducted a meta-analysis to evaluate the correlation between gene polymorphisms and adjusted plasma VPA concentration.

METHODS

The EMBASE, MEDLINE, and Cochrane Library databases were searched to obtain relevant studies. Eligible articles were reviewed, and data extraction was performed. We calculated 95% confidence intervals (CIs) and mean differences (MDs) to assess the strength of the relationship of gene polymorphisms with adjusted plasma VPA concentration.

RESULTS

The meta-analysis included 6 studies involving 847 patients with epilepsy. The pooled analysis showed that the A1075C (AA AC) polymorphism was related to the adjusted plasma concentration of VPA (P=0.02, I= 82%). Additionally, the AC phenotype statistically significantly increased the adjusted plasma VPA concentration in children compared with the mixed age subgroup (P=0.04, I= 48%). A similar association was observed between the AC phenotype for Asians (P<0.00001, I=0%) but not for Caucasians (P=0.34, I=87%).

DISCUSSION

Age might be a crucial covariate influencing the dosage-adjusted VPA concentration in patients with epilepsy. A reduced VPA dosage may be recommendable for children, particularly Asian children, who are A1075C AC carriers. Further studies could provide high-quality evidence to confirm the correlation between VPA pharmacokinetics and A1075C polymorphisms.